There are a few published reports that KRAS mutational status is associated with shorter survival in PDAC patients [5, 6] Further, there is interest in developing prognostic biomarkers for PDAC, with the mutational status of cell-free DNA, the number of circulating tumour cells, and the expression of circulating microRNAs being of current interest to pancreatic cancer research [7]. This evidence concerns the gene KRAS and neoplasm.